Docetaxel, daraxonrasib (RMC-6236) clinical trials

Phase III study of daraxonrasib (RMC-6236) in previously treated NSCLC patients with RAS mutations

This study compares a new medicine, daraxonrasib, with a standard treatment, docetaxel, for lung cancer patients whose cancer has a specific change (RAS mutation) and has been treated before. It aims to see which medicine works better.